Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Listing Update
Date:3/6/2009

"http://www.celltherapeutics.com" target="_new">www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by April 6, 2009, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutic
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
2. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
3. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
4. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
5. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
9. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
10. Pearl Therapeutics Secures $8 Million in Debt Financing
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, ... and conditions,today announced fiscal results for its second quarter ended June 30, 2009. ... Results, ... Q2 2009 Q2 ...
... ... Web 2.0 Website in an effort to not only provide circuit board assembly and design ... ... value to their current and future customers Surface Mount Solutions (SMS) has launched a new ...
... , , , ... ACTC) announced today that Dr. Robert Lanza, its Chief Scientific Officer, is ... 102 and 55 [Live Saturday 12 pm - 1 pm ET; Replays ... The show focuses on Dr. Lanza,s research at ACTC and his new ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 11Surface Mount Solutions Launches New Website 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The way indigenous cultures around the globe use,traditional medicines ... linked to the,natural environment, new research has found. ... threat that comes on top of the challenges posed ... for more than half the world,s population, with 80 ...
... Energy,s (DOE,s) Office of Science and its labs will be ... AAAS Annual Meeting,CHICAGO Attendees of the 2014 AAAS Annual ... DOE,s Office of Science and its labs will play an ... President,s Address ,2014 AAAS co-chair ...
... PITTSBURGH, Feb. 13, 2014 University of Pittsburgh Cancer Institute ... to do new tricks., By screening a library of FDA-approved ... treatment for a rare type of cancer, UPCI scientists were ... the cancer becomes resistant to standard drug treatment., The discovery, ...
Cached Biology News:Environment change threatens indigenous know-how 2Department of Energy speakers and sessions at AAAS 2Department of Energy speakers and sessions at AAAS 3Department of Energy speakers and sessions at AAAS 4Department of Energy speakers and sessions at AAAS 5Department of Energy speakers and sessions at AAAS 6Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: